Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication

Area of Science:

• Virology
• Pharmacology
• Infectious Diseases

Background:

• RNA viruses, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV), rely on host cell machinery for replication.
• Organic anion transporters (OATs) are host cell proteins crucial for viral replication.
• Probenecid is an FDA-approved drug known to inhibit OATs.

Purpose of the Study:

• To evaluate the prophylactic and therapeutic potential of probenecid against RSV replication.
• To determine the efficacy of probenecid in various in vitro and in vivo models.

Main Methods:

• In vitro studies using Vero E6, HEp-2, and primary normal human bronchoepithelial (NHBE) cells.
• In vivo studies utilizing BALB/c mice models.
• Administration of probenecid at various regimens.

Main Results:

• Nanomolar concentrations of probenecid demonstrated significant inhibition of both RSV strain A and B replication in vitro.
• Probenecid effectively inhibited RSV strain A replication in vivo in BALB/c mice.
• Probenecid exhibited prophylactic and therapeutic efficacy against RSV.

Conclusions:

• Probenecid shows promising potential as a prophylactic and chemotherapeutic agent for RSV infections.
• The drug's ability to inhibit OATs is a key mechanism for its antiviral activity.
• Further investigation into probenecid for RSV treatment is warranted.